Stryker Corporation, a Fortune 500 medical technologies firm, agreed to acquire TSO3, an innovator in sterilization technology for medical devices in healthcare, for $52m. The purchase price represents a premium of approximately 18%. R.M. Rumble, President and CEO of TSO3, stated: "TSO3's board of directors and management believe that this transaction provides the best liquidity opportunity for shareholders. Reaching this conclusion is an important step for TSO3 as well as current and future customers, as it will provide the expertise and the financial resources to best help TSO3 achieve its full potential. We look forward towards its successful completion."